Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Gastroesophageal Junction Adenocarcinoma”

122 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 122 results

Testing effectiveness (Phase 2)UnknownNCT04631757
What this trial is testing

Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital 33
Testing effectiveness (Phase 2)UnknownNCT05528367
What this trial is testing

Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Locally Advanced Gastric Cancer
Zhejiang Cancer Hospital 33
Testing effectiveness (Phase 2)Looking for participantsNCT04984733
What this trial is testing

Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer

Who this might be right for
Adenocarcinoma - GEJCancer of Esophagus
University of Southampton 18
Post-approval studies (Phase 4)Not Yet RecruitingNCT07502027
What this trial is testing

A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer (Diagnosis)Gastric Cancer (GC)Gastroesophageal Junction Adenocarcinoma
Huazhong University of Science and Technology 55
Testing effectiveness (Phase 2)UnknownNCT04202484
What this trial is testing

Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer
RenJi Hospital 20
Large-scale testing (Phase 3)Looking for participantsNCT06203600
What this trial is testing

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Who this might be right for
Advanced Esophageal AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction Adenocarcinoma+13 more
National Cancer Institute (NCI) 224
Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University 156
Testing effectiveness (Phase 2)Active Not RecruitingNCT03641313
What this trial is testing

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+5 more
National Cancer Institute (NCI) 17
Large-scale testing (Phase 3)Looking for participantsNCT07043400
What this trial is testing

Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Metastatic Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
BeOne Medicines 351
Early research (Phase 1)Active Not RecruitingNCT04007744
What this trial is testing

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8+19 more
Mayo Clinic 36
Testing effectiveness (Phase 2)Study completedNCT04014075
What this trial is testing

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Who this might be right for
Adenocarcinoma Gastric Stage IV With MetastasesAdenocarcinoma - GEJ
Daiichi Sankyo 79
Very early researchStudy completedNCT03395847
What this trial is testing

Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma

Who this might be right for
Advanced Gastroesophageal Junction AdenocarcinomaClinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8+22 more
M.D. Anderson Cancer Center 9
Testing effectiveness (Phase 2)Study completedNCT00107341
What this trial is testing

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Who this might be right for
Esophageal Cancer
Alliance for Clinical Trials in Oncology 37
Early research (Phase 1)Looking for participantsNCT04704661
What this trial is testing

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Who this might be right for
Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
National Cancer Institute (NCI) 51
Testing effectiveness (Phase 2)Looking for participantsNCT06265285
What this trial is testing

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Who this might be right for
Advanced Esophageal Squamous Cell CarcinomaAdvanced Renal Cell CarcinomaClinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8+28 more
Mayo Clinic 50
Testing effectiveness (Phase 2)Looking for participantsNCT04660760
What this trial is testing

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+28 more
Academic and Community Cancer Research United
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06241469
What this trial is testing

Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study

Who this might be right for
Gastric CancerGastroEsophageal CancerAdenocarcinoma
Wu Jun 40
Large-scale testing (Phase 3)Looking for participantsNCT07118527
What this trial is testing

A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 600
Large-scale testing (Phase 3)Study completedNCT02625623
What this trial is testing

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Who this might be right for
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaGastric Cancer Third Line
EMD Serono Research & Development Institute, Inc. 371
Load More Results
116